Data continues positive trend as additional patients are enrolled in 3 cohorts
Vaccine was safe and well tolerated by participants in all 3 cohorts
Protocol defined immune responses were exhibited in over 70% of patients
A Phase 2 study evaluating the vaccine in the neoadjuvant setting is planned to commence in 2025
SAN JOSE, Calif., Nov. 8, 2024 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of new, updated positive data from the Phase 1 clinical trial of its breast cancer vaccine (NCT04674306) at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held in Houston, Texas.
The data from the Phase 1 clinical trial of Anixa Biosciences’ breast cancer vaccine continues to show a positive trend as additional patients are enrolled in the 3 cohorts. The vaccine was found to be safe and well tolerated by participants in all 3 cohorts, with no significant adverse reactions reported. Furthermore, protocol defined immune responses were exhibited in over 70% of patients, indicating that the vaccine is eliciting the desired immune response.
The promising results from the Phase 1 trial have paved the way for a Phase 2 study to evaluate the vaccine in the neoadjuvant setting, which is set to begin in 2025. This study will further assess the safety and efficacy of the vaccine in a larger patient population, with the goal of moving closer to regulatory approval and eventual widespread use.
Overall, the data presented at the SITC 39th Annual Meeting highlights the potential of Anixa Biosciences’ breast cancer vaccine as a promising immunotherapy option for patients with breast cancer. With further research and development, this vaccine could potentially revolutionize the treatment and prevention of this deadly disease.
Based on other online sources, the positive data from the Phase 1 clinical trial of Anixa Biosciences’ breast cancer vaccine could have a significant impact on individual patients. If the vaccine proves to be safe and efficacious in the larger Phase 2 study, it could offer a new treatment option for patients with breast cancer, potentially improving outcomes and quality of life.
On a global scale, the development of a successful breast cancer vaccine could have far-reaching implications. It could help reduce the burden of breast cancer on healthcare systems worldwide, by offering a preventative measure that could potentially reduce the incidence of this disease. Additionally, it could pave the way for the development of other cancer vaccines, opening up new possibilities for the treatment and prevention of various types of cancer.
Conclusion
The positive data from the Phase 1 clinical trial of Anixa Biosciences’ breast cancer vaccine is a promising step forward in the fight against breast cancer. With further research and development, this vaccine has the potential to revolutionize the treatment and prevention of this deadly disease, offering hope to patients and healthcare systems around the world.
